New Delhi, Sept 18 (KMS): World Health Organisation’s (WHO) approval for the emergency use authorisation (EUA) to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, has been delayed till October 5.
As per WHO, the Strategic Advisory Group of Experts on Immunization (SAGE) will be meeting on October 5 to check whether to grant EUA to Covaxin or not.
The assessment of the SAGE working group on the available pieces of evidence will determine EUA.
Meanwhile, Bharat Biotech on Friday said it has submitted all the data to the World Health Organisation (WHO) for Emergency Use Listing (EUL) of its COVID-19 vaccine Covaxin and is awaiting feedback from the UN Public Health Agency.
In a series of tweets, Bharat Biotech said that Covaxin clinical trial was fully compiled and available in June 2021.
“#COVAXIN clinical trial data was fully compiled and available in June 2021. All Data was submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback,” Bharat Biotech tweeted.
The WHO has so far approved Covid vaccines developed by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca for emergency use.